Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Updates from the MEDALIST study

Amer Zeidan, MBBS, MHS, of Yale University and Yale Cancer Center, New Haven, CT, outlines results from the Phase III MEDALIST study (NCT02631070), investigating the clinical benefit of luspatercept in patients with lower-risk myelodysplastic syndrome and high transfusion burden. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).